FULGENT GENETICS, INC. Additional Paid in Capital, Common Stock
FULGENT GENETICS, INC. (FLGT) had Additional Paid in Capital, Common Stock of $524.10 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-07-30
- 2026-06-30: Additional Paid in Capital, Common Stock $524.10M.
- 2026-03-31: Additional Paid in Capital, Common Stock $540.14M.
- 2025-12-31: Additional Paid in Capital, Common Stock $574.52M.
- 2025-09-30: Additional Paid in Capital, Common Stock $565.69M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $524.10M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $540.14M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $574.52M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $565.69M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $550.60M 10-Q · filed 2025-08-01 |
| 2025-03-31 | $543.90M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $543.13M 10-K · filed 2026-02-27 |
| 2024-09-30 | $532.91M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $522.42M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $511.33M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $501.72M 10-K · filed 2025-02-28 |
| 2023-09-30 | $514.26M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $506.07M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $495.98M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $486.58M 10-K · filed 2024-02-28 |
| 2022-09-30 | $477.81M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $504.07M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $507.05M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $501.91M 10-K · filed 2023-02-28 |
| 2021-09-30 | $483.73M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $482.25M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $450.86M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $418.06M 10-K · filed 2022-02-28 |
| 2020-09-30 | $201.77M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $148.06M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $146.95M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $146.06M 10-K · filed 2021-03-08 |
| 2019-09-30 | $117.48M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $115.53M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $114.79M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $114.20M 10-K · filed 2020-03-13 |
| 2018-09-30 | $113.60M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $113.01M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $112.43M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $111.88M 10-K · filed 2019-03-22 |
| 2017-09-30 | $111.30M 10-Q · filed 2017-11-13 |
| 2016-12-31 | $109.73M 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |